The relationship between renin angiotensin system inhibitor and serum potassium increase during combination therapy with Daclatasvir and Asnaplevir for chronic hepatitis C

Abstract

To demonstrate the relationship between renin angiotensin system inhibitor (RASI) and serum potassium increase during combination therapy with Daclatasvir and Asnaplevir in 27 patients with chronic hepatitis C, we first categorized subjects according to the administration of RASI. We then evaluated a clinical characteristic, liver and renal function, serum potassium levels at the baseline and change of serum potassium levels under treatment. There were no significant differences in age, sex, liver and renal function, serum potassium levels at the baseline between groups. Serum potassium levels under treatment significantly increased in the RASI group, and hyperkalemia developed in three cases of the RASI group. The cases with serum potassium increase tended to be complicated with diabetes. It is necessary to be cautious with the serum potassium increase when we start Daclatasvir and Asnaplevir in chronic hepatitis C patients with concomitant use of RASI.